Is ResMed Inc. (CHESS) (ASX:RMD) under threat from this high growth innovator?

This New York Stock Exchange listed upstart is innovating in an industry dominated by ResMed Inc. (CHESS) (ASX: RMD)

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

"Many people have sleep apnea, but may not even know it. In fact, sleep apnea affects more than 3 in 10 men and nearly 1 in 5 women, so it's more common than you might think".

That's a direct quote from the ResMed Inc. (CHESS) (ASX: RMD) website and in my view, one of the key reasons that make Resmed an attractive investment

Like CSL Limited (ASX: CSL) and Cochlear Limited (ASX: COH), Resmed has a large total addressable market and has been capturing more of that market.

Resmed's revenues grow at double-digit rates and in the last financial year, it made US$2.3 billion in revenue. That is a lot of money for a company that still has a large market to capture.

Its no wonder then that this lucrative market has attracted competition with the latest being the New York Stock Exchange (NYSE) listed Inspire Medical Systems Inc.

Unlike Resmed's CPAP devices, Inspire's therapy devices are mainly inside the body and do not require the patient to wear a mask. The images below provide a visual comparison between a Resmed mask and Inspire's therapy.

Source: Resmed website
Source: Inspire website

I have never used a CPAP device before, but I would imagine that the mask might be more uncomfortable to use.

So is Resmed under threat from this disruptive innovator? Here are some reasons why I think investors should take the threat from Inspire seriously:

  • Whilst Inspire only started trading on the NYSE this year and has a market cap of less than US$1 billion, it is a spin-off from Medtronic PLC, another NYSE listed company which has a market cap of US$125 billion. That's the kind of backing you want to see in a small company, from a company that has a lot of relevant IP and deep pockets.
  • Inspire has a very high sales growth rate of over 80% which is very impressive, even though it's coming from a lower base compared to Resmed.
  • Inspire has higher gross margins (roughly 80% compared to Resmed's 58%) although it's not yet profitable.

Foolish Takeaway

For now, I think there is no immediate threat to Resmed's bottom line but investors will need to keep an eye on Resmed's R&D investments and how their products compare to new upstarts such as Inspire.

Motley Fool contributor Kevin Gandiya has no position in any of the stocks mentioned. You can find Kevin on Twitter @KevinGandiya. The Motley Fool Australia has recommended Cochlear Ltd. and ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Why the Mesoblast share price is diving 18% after an FDA win

Investors are sending the Mesoblast share price tumbling on Friday. But why?

Read more »

A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
Healthcare Shares

Mesoblast share price rockets 30% on big US FDA news

Big news is giving this biotech a huge lift on Thursday.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Guess which ASX healthcare stock is jumping 12% on Wednesday

This shares is rocketing this morning. But why? Let's find out.

Read more »

Man holding out Australian dollar notes, symbolising dividends.
Healthcare Shares

Here is the dividend forecast to 2029 for CSL shares

Can this blue-chip giant provide healthy dividend income?

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

The best ASX 200 healthcare stocks to buy in 2025

These shares could give your portfolio a healthy boost next year according to Bell Potter.

Read more »

In the lab at work, the mature adult woman and young adult man smile as they review the results of their successful experimentation.
Healthcare Shares

ASX 300 healthcare stock lifts off on promising new results

Up 28% in a year, the ASX healthcare stock is leaping higher on Thursday.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

If you'd invested $5,000 in this ASX 300 healthcare stock a year ago, you'd now have $30,000!

This stock has made millions for investors over just a few months.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

Has the Pro Medicus share price risen too high too quickly?

Pro Medicus shares have rocketed 173% since this time last year.

Read more »